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Abstract
Background: Mutations in the cellular prion protein associated to familial prion disorders severely increase the likelihood of
its misfolding into pathogenic conformers. Despite their postulation as incompatible elements with the native fold, these
mutations rarely modify the native state structure. However they variably have impact on the thermodynamic stability and
metabolism of PrP
C and on the properties of PrP
Sc aggregates. To investigate whether the pathogenic mutations affect the
dynamic properties of the HuPrP(125-229) a-fold and find possible common patterns of effects that could help in
prophylaxis we performed a dynamic diagnosis of ten point substitutions.
Methodology/Principal Findings: Using all-atom molecular dynamics simulations and novel analytical tools we have
explored the effect of D178N, V180I, T183A, T188K, E196K, F198S, E200K, R208H, V210I and E211Q mutations on the
dynamics of HuPrP(125-228) a-fold. We have found that while preserving the native state, all mutations produce dynamic
changes which perturb the coordination of the a2-a3 hairpin to the rest of the molecule and cause the reorganization of the
patches for intermolecular recognition, as the disappearance of those for conversion inhibitors and the emergence of an
interaction site at the b2-a2 loop region.
Conclusions/Significance: Our results suggest that pathogenic mutations share a common pattern of dynamical alterations
that converge to the conversion of the b2-a2 loop into an interacting region that can be used as target for interference
treatments in genetic diseases.
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Introduction
Prion diseases are fatal neurodegenerations of mammals
featured by the apparition of misfolded and aggregated forms of
the cellular prion protein (PrP
C) [1],[2]. These forms are
collectively referred to as disease-related prion protein (PrP
Sc)
and display self-propagative properties [1],[2]. PrP
Sc is formed
from PrP
C in a posttranslational multistep refolding process, in
which the native structure of PrP
C partially unfolds to expose
regions that direct the assembly of the yet structurally unresolved
b-sheet rich and protease resistant PrP
Sc molecular aggregates
[3–9]. Once formed, PrP
Sc self-perpetuates by propagating as a
template its fold to PrP
C [1],[2]. In human familial diseases,
mutations in the open-reading frame of PRNP produce PrP chains
with an increased likelihood for PrP
Sc formation [1],[2]. In these
cases the late-onset of the disease and the identification of
adequate pharmacological targets may allow intervention strate-
gies for asymptomatic carriers directed to retard if not abrogate
the pathogenic conversion.
NMR studies have shown that PrP
C native state is featured by
an N-terminal flexible tail and a C-terminal globular domain
(residues 125–228, human sequence numbering), with a fold
containing three a-helices and an anti-parallel b-sheet [10–13].
These elements are arranged into two halves, b1-a1-b2 and a2-
a3, that are packed against each other defining the hydrophobic
core [10–13]. Of them, the a2-a3 region behaves as an
independent folding unit, that displays unique aggregation
properties and forms the parallel in-registered b-sheet backbone
of the recombinant PrP fibrils [4],[14–17]. Despite initial
considerations, most pathogenic mutations rarely alter the native
structure of PrP
C, but perturb its stability, regulate its metabolism,
modulate the oligomerization pathways and determine the
features of the PrP
Sc assemblies [2],[4],[14],[18–27]. Moreover,
molecular dynamics (MD) studies have reported that some
mutations cause local conformational effects (as on the b2-a2
and a2-a3 regions) and affect the packing and flexibility properties
of the native state [19],[28–31]. On the other hand, studies on the
effects of oxidative modifications and of the side-chain polarity
(e.g. with M-to-S mutations) have shown that perturbations of the
native state can transmit long-range and, disturbing the network of
stabilizing interactions, facilitate the population of alternative
states, some of which may cause the routing into the productive
pathogenic conversion [31–33]. Interestingly, the long-range
propagation of perturbations has also been observed for some
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e19093mutant PrP chains [19],[33]. Theoretical approaches then suggest
that mutations provoke dynamic alterations of the native state and
that, by modifying the conformational preferences, may also
perturb its molecular recognition properties. Changes in the
exposition of binding sites for inhibitors and of segments engaged
in aggregation reactions could be crucial for the permissibility of
the pathogenic structural transitions. Also, the identification of
these regions may provide useful targets for pharmacological
interference.
To construct a global view on the role of pathological point
mutations on PrP conversion, in this study we have explored the
effect of ten mutations occurring at the a2-a3 region (namely
D178N, V180I, T183A, T188K, E196K, F198S, E200K, R208H,
V210I and E211Q) on the conformational dynamics of the native
state and of its consequences on the definition of interaction
patches. We have found that while point substitutions adapt quite
well to the native structure, they have diverse effects on its
dynamic properties. The analysis of these dynamic signatures lead
to the identification of the b2-a2 loop as a common possible site
for interaction, onto which drug design can be targeted with the
goal of interfering with the aggregation process in mutant carriers.
Results
To facilitate the identification of common patterns of behavior
and to compare with previous reports, we selected ten point
substitutions linked to familial prion diseases and a PrP sequence
having methionine at position 129 [Figure 1, Table 1]. These
mutations are located in the a2-a3 region of the C-terminal
globular domain and include substitutions of residues with both
charged and hydrophobic side chains. Of them six are associated
with Creutzfeldt-Jakob disease (CJD) [V180I, E196K, E200K,
R208H, V210I and E211Q], one with Familial Fatal Insomnia
(FFI) [D178N], two with dementia [T183A and T188K] and one
with Gerstmann-Strau ¨ssler-Scheinker syndrome (GSS) [F198S]
[Figure 1, Table 1]. For comparison we included the data from
the wild type (wt) and of the M206 and M213 sulfoxidized variants
[32]. Table 1 summarizes the features of these protein chains and
the parameters used for the simulations. The obtained trajectories
were analyzed in terms of changes on the native state flexibility,
the internal dynamics and coordination properties of the fold, the
solvent exposure of a3 methionines (M205, M206 and M213) and
the energetics of the protein surface in relation to the definition
of interaction patches linked to aggregation/self-recognition
processes.
Most mutations behave as flexibility amplifiers
The calculation of the root mean square fluctuation (RMSF) of
each residue around its average position in the respective MD
trajectory was used to analyze changes in the protein flexibility.
Consistently with previous data [32], the variation in flexibility of
the wt native state involves mainly two regions, residues 165–175
and residues 185–200, comprising the b2-a2 loop and the a2-a3
structural regions, respectively. Mutants D178N and R208H show
a general wt-like behavior, with only a slight increase between
residues 134–156 [Figure 2A]. As reported for sulfoxidized
Figure 1. 3D structure of the HuPrP(125–228) a-fold used as template for the generation of the different mutants and sulfoxidized
variants. (A) 3D structure of the HuPrP(125–228) a-fold corresponding to the Pdb entry 1QLZ used as a starting point in the simulations [18] and
depicting the different helical structures. (B) Side chains replaced for the generation of the different mutants used in this study.
doi:10.1371/journal.pone.0019093.g001
Table 1. Parameters of the HuPrP(125–228) chains used for
the simulation.
HuPrP
(125–228) Charge Time (ns)
Water
molecules Disease
wt -3 80.7 7051
MO206 -3 161.6 6432
MO213 -3 169.6 7052
MO206,MO213 -3 160 7051
D178N -1 200 7050 FFI
a
V180I -3 200 7051 CJD
T183A -3 200 7050 dementia
T188K -2 200 7047 dementia
E196K -1 200 7050 CJD
F198S -3 190 7057 GSS
E200K -1 180 7045 CJD
R208H -4 200 7056 CJD
V210I -3 200 7051 CJD
E211Q -2 200 7053 CJD
Mutants and covalent variants were generated by replacement of side chains as
indicated in the method section. The disease phenotype generated by the
mutation in the PRNP gene is also indicated [1],[2].
aSince the template chains has a methionine residue at 129, the phenotype of
D178N mutation corresponds to FFI [1],[2].
doi:10.1371/journal.pone.0019093.t001
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213) [32], the E196K, F198S, E200K, V210I and E211Q
mutations determine an enhancement of flexibility that is
restricted to the region 165–175 [Figure 2B]. Interestingly, the
RMSF pattern of both wt and E200K chains obtained here with
GROMACS reproduces the flexibility pattern generated with
AMBER [29]. Mutants V180I, T183A and T188K show a
definite increase of flexibility in both the 165–175 and the 185–
200 regions [Figure 2C]. In addition to these changes, an
increase in the flexibility around residues 220–228 forming part of
the C-terminus of a3 is also noticed in the V180I, T183A, T188K,
F198S and E211Q mutants. Then, these data supports that in
general mutations function as native state flexibility amplifiers and
subsequently they can facilitate the access to alternate conforma-
tional states.
Mutations affect the coordination of internal protein
dynamics
Since chemical changes such as those arising from mutations
can alter the dynamical states and these alterations, if significant,
must be distinctly sensed by the residues in different regions of the
protein [32],[33], we next analyzed the differential effects of the
mutations on the internal dynamics of the protein [Figure 3]. For
this purpose, we calculated the communication propensity (CP)
histograms of the different mutants of the protein [32]. It must be
stressed that in these histograms the number of residues that
communicate efficiently (y-axis) with a given target residue (x-axis)
represents a reverberation of the degree of internal coordination of
the residue-residue pairs in a protein structure and consequently it
reports on the diffusion of collective dynamic effects due to specific
perturbations. In other words, these calculations inform on the
capacity of a mutation to transmit a signal and on the identity of
the regions sensing it. Furthermore, differences between the
mutant and the wt profile may also highlight the capacity of the
mutant chain to sampling alternative states leading to the
perturbation of the native conformations.
Indeed all mutations impact on the internal coordination of the
HuPrP(125–228) a-fold and the type and magnitude of the effect
depend on the intrinsic features of the mutation, as its identity and
its positioning along the sequence [Figure 3]. Interestingly, the
dynamic effects of the mutations are not limited only to the
sequence stretch in which they are located, but are transmitted
long-range through the whole structure. As reported previously
and displayed here for an easier visualization of changes, in the
native state of wt the segment comprising b2, a2 and their
connecting loop is active in communications with a3 in a range of
15 A ˚. At increasing distances, the communications are progres-
sively reduced and no residue pairs are found to communicate at
separating distances larger than 30 A ˚. Mutations T183A and
R208H, which have opposite effects as flexibility amplifiers (largest
and none, respectively), almost completely abolish the internal
coordination of the protein. This effect was previously reported for
an artificial M206S-M213S mutant constructed to mimic the
polarity increase caused by sulfoxidation and that is partially
unstructured and prone to aggregate in solution [33]. At the
opposite side of the spectrum of effects, the T188K mutation
determines a large increase in the coordinated motions of residue
pairs. However, for this mutant the motions of the 164–174 region
appears decoupled from those of the rest of the protein.
Taking all together these data show that mutants share as
common features distinct from the wt the loss of coordination
involving residues in the 164–174, 185–205 and 218–224 regions,
comprising the b2-a2a n da2-a3 loops and the C-terminal part of
a3, respectively [Figure 3]. Importantly, the b2-a2 loop, links the
two halves of the native fold and its sequence behave as a fibrillation
motif [8],[9]. Moreover, the other regions affected are contained in
the a2-a3 helical hairpin, that behaving as an autonomous folding
unit and participating in the fibril backbone of recombinant PrP,
when isolated reproduces both the structural transition and
aggregation properties of the full length chain [14–17]. Then, these
data suggest that the lack of coordination of these stretches with the
rest of the protein could provide the conformational freedom and
flexibility necessary for the subdomaindetaching and to ease barrier
crossing to states alternative from the native conformation with
increased aggregation propensity.
Mutations increase the solvent exposure of a3
methionines facilitating their oxidation
Previous work has shown that the methionine residues forming
part of a3 encrypt a redox code for the a-fold conformational
stability, whose role in prion biogenesis is still unclear [32–36].
Oxidation of these residues, which among the different methio-
nines in the chain are those less accessible to the solvent, has been
found in aggregated PrP forms, albeit without any clear
quantitative determination of their amounts and leaving issues
open regarding their biological relevance [34–36]. Both molecular
dynamics and biophysical approaches have shown that the side
chain polarity enhancement produced by oxidation impede the
native a-fold and provide the structural flexibility required for the
acquisition of aggregation properties [31–34],[36]. Then, the
probability of the a3 methionines to undergo oxidation, which
relates to their exposure to oxidants or in general to solvent, can be
taken as a index of the acquisition of pro-aggregating features.
To gain insights into the effect of the different disease-linked
mutations on the solvent exposure of a3 methionines, we analyzed
the mutation-induced variation on the relative Solvent Accessible
Surface Area (SASA). The SASA for residues M205, M206 and
M213 was calculated by averaging along the whole simulation
time for each mutant and for the wt protein. The average SASA
value for the wt was subsequently subtracted from that of the
mutant. A positive variation indicates an increase of the solvent
exposure of M205, M206 or M213 with respect to the wt, while a
negative value reports on a decrease of solvent exposure. Figure 4
shows that except for the T188K, the presence of a mutation is
correlated to an increase of the solvent exposure of M213. This
increase varies in relative value from 0.1 in D178N to 1.4 in
R208H. In contrast, except for F198S, E200K and E211Q, most
of the mutations result in a decrease of the SASA for M206.
Regarding M205, mutations other than R208H cause a reduction
in the relative SASA average value. As noted, the T188K case
diverges from the rest of mutations in that it is the only one
inducing a reduction of the solvent exposure of all three analyzed
methionines. It is worth underlining that this is an average effect.
Indeed, analysis of the time dependence of the solvent accessible
area for M213, M205 and M205 reveals large fluctuations, with
Figure 2 Effect of mutations on the residue based average flexibility. Variation of the Root Mean Square Fluctuations (RMSF) as a function of
the residue number for the different substituted protein forms: (A) D178N (blue), R208H (red); (B) E196K (blue), F198S (purple), E200K (cyan), V210I
(red), E211Q (green); and (C) V180I (red), T183A (blue), T188K (green). For easiest comparison, the curve corresponding to the wt chain has been
included in each panel as a black thick trace.
doi:10.1371/journal.pone.0019093.g002
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residue and shows the fraction of residues of the whole protein that are highly prone to communicate with it (CP,0.025). In each histogram only
communications at distances greater than a given threshold: (,15 A ˚, black lines; .20 A ˚, red lines; .25 A ˚, green lines; and .30 A ˚, blue lines) are
considered. From top to bottom: (A) wt, T188K, V210I, E211Q; (B) D178N, V180I, E196K; and (C) T183A, F198S, E200K, R208H.
doi:10.1371/journal.pone.0019093.g003
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sensitive side chains (data not shown). However, such fluctuations
are averaged by the engagement of the mutant side chain (K188)
in a set of electrostatic intramolecular interactions with carbox-
ylate groups of E196, E200 and E207, while the rest of the protein
responds with increased flexibility and changes in dynamic
coordination as shown above. These interactions, that are pH-
dependent, then determine an average decrease of the solvent
accessible surface.
Sincemutationsaffectdifferentlythesolvent exposureofthethree
a3 methionines, we then asked how the exposure to solvent of a
single methionine would influence the exposure of the other two.
Taking into account that except for T188K, mutations increase the
exposure of M213 and assuming that once exposed it becomes
oxidized, to answer this question we analyzed the SASA variation of
M205 and M206 using the MO213 trajectories [Figure 4].
Interestingly, oxidation of M213 determines the largest relative
increase in the accessible surface area of M205 and M206,
compared to all the disease-linked mutations. Then, these data
suggest that out of the three a3 methionines M213 may be more
accessible to oxidation than its neighboring M205 and M206,
resulting ina kineticallyfaster modification of the side chain polarity
for M213. This in turn leads to larger accessibility for M205 and
M206 to possible oxidizing agents, allowing the oxidation of the
three a3 methionine residues. Indeed, the occurrence of an
increased sensitivity to oxidation in a3 methionines in mutant
chains was shown using immunological tools and recombinant full
length HuPrP wt and E200K chains [10]. On the other hand, given
the intolerance of the a-fold for polar substitutions at M205, M206
and M213, the facilitated oxidation of a3 methionines could also
explain the folding intermediate features of some PrP mutant chains
[20–23],[31],[33],[36].
It must be noted at this point, that the relationship between MD
and the experimental data considered is at most qualitative, so that
these results should be considered as the basis for further
experimental investigations to establish whether methionine
oxidation and its effect on aggregation has a real role in the
pathogenic conversion.
Mutations remodel the surface interacting properties of
the PrP a-fold
An essential aspect of the pathogenic misfolding of PrP
C is
related to the putative remodeling of sites involved in molecular
recognition events such as protein-protein and protein-ligand
interactions. Despite the lack of knowledge of the partners, the
pathogenic misfolding process can be conceived as an event in
which the sites acting as conversion inhibitors are inactivated and
those acting as effectors (as those involved in the self-assembly
process) are formed. To investigate this issue we applied the
recently developed MLCE method [37]. This computational
approach allows the prediction of protein-protein recognition sites
from the analysis of MD-based protein energetics. The method is
based on the rationale that interaction sites are generally
characterized by non-optimized intramolecular interaction net-
works, so that they may undergo conformational changes and be
recognized by a binding partner with minimal energetic expense.
It must be noted here that, as a consequence of its physical
formulation, the MLCE method does not make a distinction
between small-molecule binding sites or protein-protein interac-
tions sites, identifying all sites where an interaction with a second
molecule is possible or favourable. Interestingly, these interaction
sites usually correspond to localized sub-structures of the protein
that are exposed or easily accessible on the protein surface. In this
context, by perturbing the intramolecular energy of interaction
networks, mutations can not only affect the stability but also the
recognition properties of PrP [12],[18],[19],[28–31],[37].
Application of the MLCE analysis to HuPrP(125–228) wt
identifies two potential interacting sites at the 141–147 and 187–
Figure 4. Effect of mutations and covalent modifications on the solvent exposure of a3-methionines. Displayed SASA values for M205,
M206 and M213 correspond to the difference SASAmut –SASAwt, where mut refers to mutant or covalently modified PrP chain and wt to wild type.
doi:10.1371/journal.pone.0019093.g004
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shown in [38–41], the 141–147 region is contained in the
epitopes of the anti-PrP
C 6H4, D18, POM1 and ICSM 18
antibodies, some of which have been shown to clear cells from
prions and inhibit their formation. On the other hand, the 187–
198 region overlaps partially the binding site for GN8, a small
molecule that acting as chemical chaperone stabilizes the native
PrP
C conformation and prevents its conversion to PrP
Sc
[42],[43]. Then, the MCLE analysis of the wt native state reveals
two interacting interfaces for PrP
C ligands acting as inhibitors of
the misfolding process, either through antibody binding (residues
141–147) or through chemical chaperone interference (residues
187–198).
In the mutant chains studied here, except in R208H and
V210I that retain the wt pattern, the putative 141–147
interacting region observed for the wt shifts to the region 160–
173, comprising the b2-a2l o o p[ Figure 5]. In addition,
mutations also affect the length and location of the second
epitope of the wt (residues 187–198). This region preserved the wt
trend in V180I, T188K, E200K, and E211Q mutations, is
expanded in F198S and V210I, and becomes shortened in
T183A, D178N and E196K. These variations may encipher
changes in the specificity and affinity of the ligands binding to it.
The shift from the 141–147 to the 160–173 region indicates that
mutations dictate the disappearance of the binding site for proven
conversion inhibitors [38],[40],[42]. On the other hand, the
identity of generated interacting site has major implications in the
pathogenic conversion process. Previous work has shown that the
b2-a2 loop forms part of the hypothetical ‘‘protein X’’ epitope
which regulates the efficiency of the in vivo template-driven
amplification of a prion [44]. Also, synthetic peptides overlapping
this region inhibit the conversion reaction [45]. In addition, this
region contains the motives ruling scrapie susceptibility in ovine
and forms part of the binding site for therapeutically active
cationic porphyrines [46–48]. The b2-a2 loop also entails a
conformational complexity that encodes the efficiency of the
protein conversion and importantly, behaves as a motif with self-
assembly properties [9],[13],[49],[50]. Then, these evidences
suggest that mutations behave as effectors for the definition of
possible interactions sites. Moreover, the variation in the
molecular recognition properties of the interfaces may also
provide a qualitative explanation to the observed variety of
oligomerization mechanisms and oligomeric structures [14].
As noted, V210I and R208H mutants diverge from the rest of
the mutants studied. [Figure 5]. Both mutants share an increased
exposure of M213 and for R208H also of M205, suggesting that
under an oxidative environment the a3 methionines could exist as
sulfoxides [Figure 4]. Strikingly, the oxidation of a3 methionines
determines the same shift in the putative recognition region as
observed for pathogenic mutations. In this case, the interacting
properties of V210I and R208H could be approximated to that of
the sulfoxidized proteins, which importantly overlaps the common
pattern identified for the rest of the mutations. Then, the
energetics-based prediction of PrP interaction surfaces suggests
that mutations cause a common variation of the putative protein-
protein recognition sites, which is featured by the loss of binding
sites for conversion inhibitors and the gain of an interacting region
at the amyloid-forming b2-a2 loop.
Figure 5. Effect of mutations on the reactive regions and sites of HuPrP(125–228). (A) Prediction of recognition regions by the MCLE
analysis. The regions fulfilling the criteria for acting as interacting sites are depicted by colored boxes at their sequence position. The chain is
indicated at the right. (B) 3D plot of the location of regions with interaction properties in the different HuPrP(121–228) variants.
doi:10.1371/journal.pone.0019093.g005
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Despite important advances in the last decade, the role that
pathogenic mutations identified in the human PrP play in favoring
the production of misfolded forms and of disease remains an open
issue. Answering these mechanistic questions is essential for the
design and development of prophylactic strategies for delaying the
disease onset in asymptomatic carriers. Using the native state as
the prevalent form and focusing on the early events, we have
shown here that combining the observations from all-atom
simulations of ten PrP pathogenic mutants contained in the a2-
a3 region, depicts a common perturbation pathway that is
supported by previous unrelated experimental findings. The
obtained results show that mutations alter the flexibility and the
coordination properties of the native state, with a specific impact
on the dynamics of the a2-a3 helical hairpin, which in turn modify
the protein interactive surface impinging on the binding sites for
conversion inhibitors and activating the interacting properties of
the b2-a2 loop [Figure 6].
W h i l et h ep r o t e i ni ss t i l li nt h en a t i v es t a t ea n dt h e r e f o r ef u n c t i o n a l ,
the studied mutations perturb the conformational dynamics. As a
general effect andinagreement withprevious reports,most mutations
behave as flexibility amplifiers which favors the access to otherwise
impeded states [19],[30–32]. Importantly, the detected perturbations
transmit through the protein chain to sites distant from the mutation
position. In particular, the alterations are sensed by the b2-a2l o o p ,
the C-terminal region of a2, part of the a2-a3 loop, and the C-
terminal part of a3. These effects are reminiscent of those caused by
the polar perturbations of a3 methionines [32],[33]. Moreover, the
long range effects of sequence variation have emerged as a general
property of many proteins [51–53]. All the affected regions are
endowed with proven importance in driving fibrillation processes
[4],[8],[14],[15]. The b2-a2 loop, which links the two halves of the
native fold, contains a motif that drives amyloid formation when
inserted in an unrelated protein [8],[9]. The other two regions are
contained in the a2-a3 subdomain, which participates in the
backbone of recombinant PrP fibrils [16],[17]. Interestingly, the
a2-a3 subdomain was also identified as the most relevant region for
PrP oligomerization. Despite the presence of two sequences
undergoing fast fibrillation, the a2-a3 hairpin behaves as a stable,
independently structurally stable folded unit when isolated from the
context of the whole protein [4],[14],[15]. Furthermore, chromatog-
raphy and light scattering experiments showed that the a2-a3
oligomerization pattern recapitulate that of the full-length protein
[14]. Moreover, except for T188K, mutations also increase the
average solvent exposure of M213 compared to the wt, a factor that
may facilitate the oxidation of its side chain by external agents. In
turn, M213 oxidation facilitates the oxidation of M205 and M206, all
immunologically proven as covalent features of aggregated human
PrP chains [34–36]. The quantitative determination of the amounts
of oxidized protein, the relevance of the in vitro experimental
conditions to the in vivo situation and of this factor as a trigger for
pathogenic conversion, are still open issues that need to be further
investigated at the mechanistic, biochemical and structural levels.
MD based results thus constitute a working hypothesis for new
investigations to ascertain the role of covalent modifications in PrP
pathogenic pathways.
All the changes in the native state dynamics induced by the
mutations reverberate as a reorganization of reactive regions, sites
entailing the recognition of small molecules, antibodies or self-
association events. In the wt form the interaction hot-spots appear
at the 141–147 and 187–198 regions, both proven sites for the
binding of conversion inhibitors [38][40][42–43]. In contrast, in
the mutants, either directly or as consequence of a facilitated
putative M213 oxidation as for V210I and R208H, the interacting
regions change. This change is featured by the disappearance of
the 141–147 inhibitor binding site and the emergence of the 166–
179 stretch (b2-a2 loop) as interacting site. The capacity of the b2-
a2 loop to participate in both heterologous and homologous
intermolecular interaction has been experimentally shown vali-
dating the site reactivity [9],[39],[44]. On the other hand, the
inhibition of wt PrP conversion reactions by synthetic peptides
overlapping the b2-a2 loop suggests that the acquisition of binding
properties by this loop is a general step in the prion formation and
validates its behavior as pharmacological target [45].
Our results have also important mechanistic implications for the
initial steps of the pathogenic conversion process. According to Rezaei
and coworkers [15], the oligomerization process of PrP would start
with the disruption of the interactions of the a2-a3 helical hairpin with
Figure 6. Dynamic diagnosis of PrP mutations. HuPrP(121–228) fold displays interacting sites at regions located in a1 and in a2 (depicted in
red) to which antibodies and small molecules behaving as conversion inhibitors bind. Presence of a pathogenic mutation or under conditions
favoring the oxidation of the a3 methionines triggers a surface reactivity remodeling featured by the emergence of reactive features at the b2-a2
loop that dictates the engagement into the pathogenic route or that can be attenuated by its use as target for interference.
doi:10.1371/journal.pone.0019093.g006
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elements. In this framework, our theoretical results show that
pathogenic mutations facilitate the disruption of such interactions,
acting as effectors for the detachment process. Since most mutations
increase the solvent exposure of a3 methionines, possibly easing their
oxidation, and polar substitutions of those side chains impair the native
tertiary structure, it seems plausible to hypothesize that sulfoxidation
may be simply chemically tagging the detachment and allowing its
irreversibility provided the impairment of its enzymatic reduction
[33],[36],[54],[55]. Indeed, full-length chains with M206S and M213S
mutations oligomerize in the absence of denaturants as the isolate a2-
a3 hairpin [14],[15],[33]. The a2-a3 hairpin independence is
accompanied by the gain of intermolecular recognition properties at
the b2-a2 loop. By acting either as a fibrillation motif or as part of the
‘‘protein X’’ epitope, the reactivity of the b2-a2 loop may dictate the
structural transition outcome [8],[9],[44].
This dynamic and energetic model of PrP
C conformational
perturbation corroborates these experimental observations: mutations
alter the properties of the native state to different extents so that
unfolding can take different pathways, giving rise to different
conformations of partially unfolded states and/or populating different
intermediates as found in the folding kinetics studies [23]. The
observed differential perturbations of the native state dynamic
properties and reactive surfaces may thus account for the accessibility
to different PrP
Sc conformers and the possibility to form structurally
different oligomers resulting from distinct kinetic pathways [56]. This
would also explain the lack of correlation between the different stability
of the native state and of the pathogenic conversion susceptibility in PrP
mutant chains [18]. Despite its early obligatory character, the
perturbation in the dynamics and consequent destabilization of native
state does not provide the full molecular picture for the pathogenic
conversion of PrP
C. Polymerization, which is correlated to the stability
of each of the species involved (PrP
Sc conformers forming pathogenic
oligomers, heterogeneous oligomers, etc), plays an important role. In
this context, the full characterization of the conformational preferences
of the PrP
Sc conformers involved and the understanding of the effects
of mutations on their stabilities is required. PrP
Sc conformers with
different (relative) stabilities can in fact yield assemblies that have
different quaternary organizations, solubility and toxicity. This aspect is
however out of the reach of the simulations presented here. In order to
apply our approach to PrP
Sc, reliable models of the respective
structures should be available. A step into this direction may be
represented by the study of Chakroun et al. [14], whereby the structural
properties of the isolate a2-a3 region, which recapitulates the
amyloidogenic features of the whole protein and contains the
mutations herein studied, have been elucidated by means of MD,
generating a as the isolate b-sheet rich conformation consistent with
experimental observations. In any case, the generation and validation
of yet unavailable reliable structural models is an absolute requirement.
Overall our results show that the perturbations impinged by
mutations on the native PrP
C native state are dynamic in nature and
converge to the generation of a novel interactive patch at the region
constituted by the b2-a2 loop that due to its proven interacting capacity
could be used for targeted interference and provide a valid strategy to
interfere with the pathogenic conversion in mutant carriers.
Materials and Methods
Molecular dynamics
The 3D structure of the HuPrP(125–228) (Pdb entry 1QLZ) was
used as a starting point in the simulations [11]. Mutants were
generated by side chain replacement using the MUTATE command
of the WHATIF package [33],[57]. The oxidation variants at the
different Met residues were generated as described [32]. For each
system, two independent long-time scale all-atom molecular
dynamics(MD)simulationsinexplicit waterat 310K,withsimulation
times of at least 100 were independently run using different sets of
initial velocities. The analysis was carried out on the total trajectory
obtained by the combination of the two simulations for each system.
The details on the force fields and on the simulations are reported in
the supporting information (Supplementary Materials S1).
Analysis of signal propagation
The analysis of the signal propagation and internal dynamic
coordination as a function of the sequence changes was performed
as described [32–33]. The communication propensity (CP) of any
pair of residues is defined as the mean-square fluctuation of the
inter-residue distance, defining dij as distance between the Ca
atoms of residue i and residue j, respectively:
CP~S dij{dij,ave
 2T
Projection of these quantities on the 3D structures of the protein allows
the evaluation of differences in the intra-protein dynamical redistribu-
tions of interactions. For discriminating fast communications the
threshold was set at CP=0.25 and used a histogram representation to
evaluate the signaling behavior of all amino acids in the protein.
Prediction of protein interaction surfaces and epitope
identification
The identification of putative protein interaction surfaces was
carried out using the MLCE method [37]. As described in the
supporting information (Supplementary Materials S1), this approach to
define interaction sites stems from topological and energetic consi-
derations. Protein substructures involved in the recognition of binding
partners define continuous patches on the surface and can be
characterized by the ability to visit multiple conformations, a subset
of which may be optimally selected by the binding partner. In this
frame of thought, the sites that constitute an interaction patch are
contiguous in space and are characterized by non-optimized (minimal)
energetic-couplings with other residues in the protein. The map of pair
energy-couplings filtered with topological information obtainable from
the contact map can thus be used to identify local couplings
characterized by energetic interactions of minimal intensities. While
low intensity couplings between distant residues in the structure are a
trivial consequence of the distance-dependence of energy functions,
local low energy couplings identify sites whose interaction-networks are
not energetically optimized.
Solvent accessible surface area (SASA) analysis
The SASA values for all the protein residues were calculated using
the program ICM [Molsoft LLC, http://www.molsoft.com]. For every
trajectory, one snapshot every 100 ps was extracted and SASA values
were calculated using the ‘‘surface area’’ function of ICM package, the
mean values were obtained by simple arithmetic average calculation.
Supporting Information
Materials S1
(DOC)
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